CHRNE Receptor: A Potential Drug Target for Muscle Physiology and Cancer

Target Name: CHRNE

NCBI ID: G1145

CHRNE

CHRNE Receptor: A Potential Drug Target for Muscle Physiology and Cancer

CHRNE (Acetylcholine Receptor, Nicotinic, Epsilon) is a protein that plays a crucial role in muscle physiology, and is potential drug target or biomarker. It is a transmembrane receptor that is located in the muscle fibers, and is involved in the regulation of muscle contractions. The CHRNE gene was first identified in 2004, and has since been shown to be involved in a wide range of physiological processes in muscle, including muscle growth, muscle fatigue, and muscle protection.

CHRNE Receptor

The CHRNE receptor is a protein that is composed of four transmembrane segments. The first segment consists of an extracellular domain that is involved in cell signaling, and the second segment consists of an intracellular domain that is involved in protein-protein interactions. The intracellular domain of the CHRNE receptor contains a coiled-coil structure that is responsible for the receptor's ability to interact with other proteins.

The CHRNE receptor is activated by the neurotransmitter acetylcholine, which is released by the brain in response to the consumption of certain foods. When acetylcholine binds to the CHRNE receptor, it causes a conformational change that results in the formation of a cation-dependent ion channel. This channel allows the muscle fibers to become more conductive, allowing the muscle to contract.

CHRNE Receptor Signaling

The CHRNE receptor is involved in a wide range of physiological processes in muscle, including muscle growth, muscle fatigue, and muscle protection. One of the key mechanisms by which the CHRNE receptor is involved in muscle physiology is through its role in muscle fatigue.

When the muscle fibers become fatigued, the CHRNE receptor is activated, and the release of acetylcholine is increased. This increase in acetylcholine causes the muscle fibers to become less conductive, leading to a decrease in muscle contraction. Additionally, the CHRNE receptor is involved in the regulation of muscle cell survival, and has been shown to play a role in the development of muscle cancer.

CHRNE Receptor Inhibition

The CHRNE receptor is an attractive drug target because of its involvement in muscle physiology and its potential role in the development of muscle cancer. Currently, there are several drugs that are being developed to inhibit the CHRNE receptor, including n nicotinic acid, which is a competitive inhibitor of the CHRNE receptor.

Nicotinic acid is a naturally occurring compound that is found in many fruits and vegetables. It has been shown to be an effective inhibitor of the CHRNE receptor, and has been shown to have a wide range of potential therapeutic applications, including the treatment of chronic pain, anxiety, and cancer.

In conclusion, the CHRNE receptor is a protein that plays a crucial role in muscle physiology, and is potential drug target or biomarker. Its involvement in muscle growth, muscle fatigue, and muscle cancer makes it an attractive target for drug development. The use of n nicotinic acid as an inhibitor of the CHRNE receptor is an promising approach to the development of new therapeutic treatments.

Protein Name: Cholinergic Receptor Nicotinic Epsilon Subunit

Functions: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

The "CHRNE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRNE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets